top of page

PUBLICATIONS

​For more details see my google scholar page or my CV

​

  1. M. LACY,  & A.L. JENNER (2024) “Impact of resistance on therapeutic design: a Moran model of cancer growth”. Bulletin of Mathematical Biology (Accepted)

  2. X. WANG, A.L. JENNER … & C. Drovandi,  (2024) "Calibration of agent based models for monophasic and biphasic tumour growth using approximate Bayesian computation." Journal of Mathematical Biology 88 (3), 28

  3. D.P.J. GERMANO, …A.L. JENNER., …(2024) “Active remodelling of tissues to describe biphasic rheological responses” The ANZIAM Journal, 1-20

  4. J. LE SAUTEUR-ROBITAILLE, P. CROSLEY, M. HITT, A. L. JENNER, & M. CRAIG (2023). “Mathematical modeling predicts pathways to successful implementation of combination TRAIL-producing oncolytic virus and PAC-1 to treat granulosa cell tumors of the ovary.” Cancer Biology & Therapy, 24 (1), 2283926

  5. M. DALLASTON, …, A.L. JENNER (2023) “The effect of chemotaxis on T-cell regulatory dynamics.” Journal of Mathematical Biology 87 (6), 84.

  6. A.L. JENNER & P.M. BURRAGE (2023) “Modelling the flow through ion channels at the cell membrane.” International Journal of Mathematical Education in Science and Technology, 1-19.

  7. A. SURENDRAN, J. LE SAUTEUR-ROBITAILLE., … A.L. JENNER &  M CRAIG. (2023). “Approaches to generating virtual patient cohorts with applications in oncology.” Personalized Medicine Meets Artificial Intelligence: Beyond “Hype”, Towards the Metaverse. 97-119.

  8. G. WEATHERLEY, R.P. ARAUJO, S.J. DANDO & A.L. JENNER (2023) “Could Mathematics be the key to unlocking the mysteries of multiple sclerosis.” Bulletin of Mathematical Biology, 85(8), 75.

  9. J.J, BON ... A.L. JENNER, …& X. WANG (2023). “Being Bayesian in the 2020s: opportunities and challenges in the practice of modern applied Bayesian statistics.” Philosophical Transactions of the Royal Society A, 2247, 381, 20220156

  10. A.L. JENNER, ..., S.J. WADE, K.L. VINE (2023). “Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.” PLOS Computational Biology, 19(1), e1010104.

  11. S. GAZEAU., …, A.L., JENNER, & M. CRAIG (2023). “The race to understand immunopathology in COVID-19: perspectives on the impact of quantitative approaches to understand within-host interactions.” ImmunoInformatics 100021

  12. A.L. JENNER, ..., A. GOLDMAN, M. CRAIG (2022), "Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy" iScience

  13. A.P. BROWNING, ..., M.J. SIMPSON, A.L. JENNER (2022), "Identifying cell-to-cell variability in internalisation using flow cytometry" Journal of the Royal Society Interface

  14. C.E. ENGELAND, J.P.W. HEIDBUECHEL, R.P. ARAUJO, A.L. JENNER (2022), "Improving immunovirotherapies: the intersection of mathematical modelling and experiments" ImmunoInformatics

  15. C. DROVANDI, B. LAWSO, A.L. JENNER, A.P. BROWNING (2022), "Population calibration using likelihood-free Bayesian inference" arXiv

  16. A. SURENDRAN,... , A.L. JENNER, M. CRAIG (2022), "Approaches to generating virtual patient cohorts with applications in oncology" bioRxiv

  17. O. CARDINAL, ... M. CRAIG, A.L. JENNER (2022), "Establishing combination PAC-1 and TRAIL regimens for treating ovarian cancer based on specific pharmacokinetic profiles using in silico clinical trails" Computational and Systems Oncology. 

  18. A.L. JENNERL, R. AOGO, S. ALFONSO, V. CROWE, A.P. SMITH, P.A. MOREL, C.L. DAVIS, A.M. SMITH, M. CRAIG (2020), "COVID-19 virtual patient cohort reveals immune mechanisms driving disease outcomes" PLOS Pathogens

  19. P. CROSLEY, A. FARKKILA, A.L. JENNER, ..... M. CRAIG, ... M.M. HITT (2020), "Procaspase-activating compound-1 synergizes with TRAIL to induce apoptosis in established granulosa cell tumour cell line (KGN) and primary granulosa cell tumour cells in vitro" International Journal of Molecular Sciences 

  20. Y. WANG, G. AN, A. BECKER, M. CRAIG,.... A.L. JENNER.....P. MACKLIN (2020), "Rapid community-driven development of a SARS-CoV-2 tissue simulator" BioRxiv

  21. A.L. JENNER, T. CASSIDY, K. BELAID, M.C. BOURGEOIS-DAIGNEAULT, M. CRAIG (2020), “In silico trails predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumour aggressivity”, Journal for ImmunoTherapy of Cancer 

  22. S. ALFONSA, A.L. JENNER, M.CRAIG (2020), “Translational approaches to treating dynamical diseases through in silico clinical trails”, Chaos: An interdisciplinary Journal of Nonlinear Science 30:123128

  23. M. CRAIG, A.L. JENNER, B. NAMGUNG, L. LEE, A. GOLDMAN (2020), “Engineering in Medicine to address the challenge of cancer drug resistance: From micro- and nanotechnologies to computational and mathematical modelling”, Chemical Reviews

  24. A.L. JENNER, R.A. AOGO, C.L. DAVIS, A.M. SMITH, M. CRAIG (2020), “Leveraging Computational Modelling to Understand Infectious Diseases”, Current Pathobiology 1-13

  25. A.L. JENNER, F. FRASCOLI, C.O. YUN, P.S. KIM (2020), “Optimising Hydrogel Release Profiles for Viro-Immunotherapy Using Oncolytic Adenovirus Expressing IL-12 and GM-CSF with Immature Dendritic Cells”, Applied Science 10(8):2872

  26. T. LEE, A.L. JENNER, P.S. KIM, J.LEE (2020), “Application of control theory in a delayed-infection and immune-evading oncolytic virotherapy”, Mathematical Biosciences and Engineering 17(3): 2361

  27. A.L. JENNER, F. FRASCOLI, A.C.F. COSTER, P.S. KIM (2019), “Enhancing oncolytic virotherapy: Observations from a Voronoi Cell-Based model”, Journal of Theoretical Biology 485: 110052

  28. A.L. JENNER, P.S. KIM, F. FRASCOLI (2019), “Oncolytic virotherapy for tumours following a Gompertz growth law”, Journal of Theoretical Biology 480: 129-140

  29. A.L. JENNER, C.O. YUN, A. YOON, P.S. KIM, A.C.F. COSTER (2018), “Modelling heterogeneity in viral-tumour dynamics: The effects of gene-attenuation on viral characteristics”, Journal of Theoretical Biology 454: 41-52

  30. A.L. JENNER, C.O. YUN, A. YOON, A.C.F. COSTER, P.S. KIM (2018), "Modelling combined virotherapy and immunotherapy: strengthening the antitumour immune response mediated by IL-12 and GM-CSF expression", Letters in Biomathematics 5(2): S99-S116

  31. A.L. JENNER, A.C.F. COSTER, P.S. KIM, F. FRASCOLI (2018), “Treating cancerous cells with viruses: insights from a minimal model for oncolytic virotherapy”, Letters in Biomathematics 5(sup1): S117-S136

  32. A.L. JENNER, C.O. YUN, P.S. KIM, A.C.F. COSTER (2018), “Mathematical modelling of the interaction between cancer cells and an oncolytic virus: insights into the effects of treatment protocols”, Bulletin of Mathematical Biology 80(6): 1615-1629

​

​

bottom of page